/BLCO
BLCO Stock - Bausch + Lomb Corporation
Healthcare|Medical - Instruments & SuppliesNYSE
$16.98+0.47%
+$0.08 (+0.47%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).62
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6.0%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BLCO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.81 – $17.15
TARGET (TP)$18.00
STOP LOSS$15.62
RISK/REWARD1:0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$18.55
52W Low$10.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B |
| Gross Profit | $2.92B | $2.50B | $2.25B | $2.30B | $2.13B |
| Gross Margin | 60.9% | 60.4% | 59.7% | 61.0% | 62.3% |
| Operating Income | $162.00M | $130.00M | $207.00M | $329.00M | $260.00M |
| Net Income | $-317,000,000 | $-260,000,000 | $6.00M | $182.00M | $-18,000,000 |
| Net Margin | -6.6% | -6.3% | 0.2% | 4.8% | -0.5% |
| EPS | $-0.90 | $-0.74 | $0.04 | $0.52 | $-0.05 |
Company Overview
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
50%
Hold / Neutral
12
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
12 Bullish12 Neutral/Bearish
Price Targets
$21
Average Target
↑ 21.0% Upside
Now
$15
Low
$21
Average
$35
High
Based on 26 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Citigroup | Upgrade | Buy | $20 |
| December 2nd 2025 | Morgan Stanley | Upgrade | Overweight | $21 |
| October 1st 2025 | Goldman | Initiation | Neutral | $16 |
| May 2nd 2025 | H.C. Wainwright | Reiterated | Buy | $15← $20 |
| March 28th 2025 | Wells Fargo | Downgrade | Equal Weight | $15← $24 |
| December 11th 2024 | Citigroup | Downgrade | Neutral | $22← $24 |
| December 2nd 2024 | Morgan Stanley | Downgrade | Equal Weight | $19 |
| October 15th 2024 | Evercore ISI | Upgrade | Outperform | $25← $19 |
| July 10th 2024 | Raymond James | Initiation | Outperform | $19 |
| May 6th 2024 | Morgan Stanley | Upgrade | Overweight | $18← $16 |
| January 4th 2024 | Evercore ISI | Downgrade | In-line | $17← $19 |
| December 12th 2023 | Stifel | Initiation | Hold | $16 |
| October 3rd 2023 | Evercore ISI | Resumed | Outperform | $20 |
| May 30th 2023 | Morgan Stanley | Resumed | Equal Weight | $20 |
| March 9th 2023 | Needham | Initiation | Hold | - |
Earnings History & Surprises
BLCOBeat Rate
67%
Last 15 quarters
Avg Surprise
-17.3%
EPS vs Estimate
Beats / Misses
10/4
1 met exactly
Latest EPS
$0.18
Q4 2025
EPS Surprise History
Q1 24
+41.2%
$0.24vs$0.17
Q2 24
-22.2%
$0.07vs$0.09
Q3 24
0.0%
$0.13vs$0.13
Q4 24
+6.3%
$0.17vs$0.16
Q1 25
+4.2%
$0.25vs$0.24
Q2 25
-333.3%
$-0.07vs$0.03
Q3 25
+16.7%
$0.07vs$0.06
Q4 25
+12.5%
$0.18vs$0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 18, 2026 | $0.35 | — | — | — |
Q4 2025 | Oct 29, 2025 | $0.16 | $0.18 | +12.5% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $0.03 | $-0.07 | -333.3% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $0.24 | $0.25 | +4.2% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.16 | $0.17 | +6.3% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.13 | $0.13 | 0.0% | = MET |
Q2 2024 | May 1, 2024 | $0.09 | $0.07 | -22.2% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $0.17 | $0.24 | +41.2% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.18 | $0.22 | +22.2% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.16 | $0.18 | +12.5% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.14 | $0.10 | -28.6% | ✗ MISS |
Q1 2023 | Feb 22, 2023 | $0.22 | $0.23 | +4.5% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.23 | $0.31 | +34.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.20 | $0.29 | +45.0% | ✓ BEAT |
Q2 2022 | May 6, 2022 | $0.23 | $0.06 | -75.6% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $0.15 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.17 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.13 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.08 | — | — |
Latest News
Cooper Cos. jumps after starting strategic review, naming new board chair
📈 PositiveSeeking Alpha•Dec 4, 2025, 09:54 PM•Also:
Morgan Stanley Upgrades Bausch & Lomb to Overweight, Raises Price Target to $21
📈 PositiveBenzinga•Dec 2, 2025, 05:25 PM
RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to C$19
📈 PositiveBenzinga•Nov 14, 2025, 03:44 PM
RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $19
📈 PositiveBenzinga•Nov 14, 2025, 03:40 PM
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $17
➖ NeutralBenzinga•Nov 14, 2025, 03:15 PM
Barclays Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $17
📈 PositiveBenzinga•Oct 31, 2025, 03:17 PM•Also:
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $17
📈 PositiveBenzinga•Oct 31, 2025, 10:56 AM
JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $16
➖ NeutralBenzinga•Oct 30, 2025, 08:42 PM
Evercore ISI Group Maintains Outperform on Bausch & Lomb, Raises Price Target to $18
📈 PositiveBenzinga•Oct 30, 2025, 04:17 PM
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $16
➖ NeutralBenzinga•Oct 30, 2025, 02:37 PM
Raymond James Reiterates Outperform on Bausch & Lomb, Raises Price Target to $19
📈 PositiveBenzinga•Oct 30, 2025, 02:32 PM
Bausch & Lomb Q3 Adj. EPS $0.18 Beats $0.16 Estimate, Sales $1.281B Beat $1.279B Estimate
📈 PositiveBenzinga•Oct 29, 2025, 10:59 AM
Bausch & Lomb Affirms FY2025 Sales Guidance of $5.050B-$5.150B vs $5.088B Est
➖ NeutralBenzinga•Oct 29, 2025, 10:59 AM
Bausch & Lomb Q3 Adj. EPS $0.18 Beats $0.16 Estimate, Sales $1.281B Inline
📈 PositiveBenzinga•Oct 29, 2025, 10:58 AM
Evercore ISI Group Maintains Outperform on Bausch & Lomb, Raises Price Target to $17
📈 PositiveBenzinga•Oct 7, 2025, 04:32 PM
Goldman Sachs Initiates Coverage On Bausch & Lomb with Neutral Rating, Announces Price Target of $16
➖ NeutralBenzinga•Oct 1, 2025, 05:50 PM
Frequently Asked Questions about BLCO
What is BLCO's current stock price?
Bausch + Lomb Corporation (BLCO) is currently trading at $16.98 per share. The stock has moved +0.47% today.
What is the analyst price target for BLCO?
The average analyst price target for BLCO is $18.00, based on 1 analyst.
What sector is Bausch + Lomb Corporation in?
Bausch + Lomb Corporation operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NYSE exchange.
What is BLCO's market cap?
Bausch + Lomb Corporation has a market capitalization of $6.01 billion, making it a mid-cap company.
Does BLCO pay dividends?
No, Bausch + Lomb Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
GKOS
Glaukos Corporation
$116.22
Mkt Cap: $6.7B
MMSI
Merit Medical Systems, Inc.
$87.70
Mkt Cap: $5.2B
OSCR
Oscar Health, Inc.
$14.90
Mkt Cap: $3.8B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
PTCT
PTC Therapeutics, Inc.
$78.57
Mkt Cap: $6.3B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
Explore stocks similar to BLCO for comparison